Product logins

Find logins to all Clarivate products below.


Allergic Rhinitis | Treatment Algorithms: Claims Data Analysis | US | 2019

Allergic rhinitis is a chronic immunoglobulin E-mediated respiratory response to environmental allergens. It is typically treated with intranasal corticosteroids, followed by antihistamines, mast cell stabilizers, decongestants, leukotriene antagonists, and/or anticholinergics. Allergen immunotherapy can target specific environmental allergies and work to change the response of the patient’s immune system to the allergen. The biological therapies that target circulating free IgE, such as Xolair, may be a promising novel approach to treating the disease. The availability of allergen immunotherapy and the potential of biological therapies with novel mechanisms of action are expanding physicians’ treatment arsenal and fueling competition in the allergic rhinitis therapy market.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed allergic rhinitis patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed allergic rhinitis patients?
  • How have allergen immunotherapies and/or biologics been integrated into the treatment algorithm, and what is their source of business?
  • What percentage of allergic rhinitis patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
  • What percentage of allergic rhinitis patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Related Market Assessment Reports

Report
Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms: Claims Data Analysis – Immune Thrombocytopenic Purpura (US)
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count, resulting in an increased risk of bleeding. Current therapies for ITP can be largely divided…
Report
Myasthenia Gravis – Geography Focus: China – China In-Depth: Myasthenia Gravis
China’s myasthenia gravis (MG) market is transitioning from long-standing symptomatic regimens toward a more structured mix of targeted therapies that increasingly shape treatment pathways…
Report
Alopecia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alopecia Areata (US)
Alopecia areata (AA) is an autoimmune condition in which the immune-mediated damage to hair follicles results in patchy or extensive hair loss. AA treatment is evolving rapidly as dermatologists…
Report
Psoriatic Arthritis – Unmet Need – Unmet Need – Psoriatic Arthritis (US/EU)
The psoriatic arthritis (PsA) therapy market is on a growth trajectory, fueled by the disease’s increasing prevalence, innovative treatment options, and heightened patient awareness. TNF-alpha…
Report
Chronic Urticaria – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Spontaneous Urticaria (US)
The treatment landscape for chronic spontaneous urticaria (CSU) remains largely driven by oral therapies, including approved antihistamines and off-label agents such as DMARDs and…